Patent ID: 9095600
Filing Date: 2015-08-04
Classification: A61K,A61P

Abstract:
1. A method for treatment of myocardial ischemia-reperfusion injury without an increase in collateral blood flow, the method comprising administering an active agent consisting of a lipid membrane structure retaining adenosine to a subject in need thereof, wherein said administering is intravenously, wherein the lipid membrane structure contains (i) a phospholipid, (ii) a cholesterol and/or a cholestanol, and (iii) a polyethylene glycol derivative selected from the group consisting of N-{carbonyl-methoxypolyethylene glycol-2000}-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, N-{carbonyl-methoxypolyethylene glycol-5000}-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, N-{carbonyl-methoxy-polyethylene glycol-750}-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, N-{carbonyl-methoxy-polyethylene glycol-2000}-1,2-distearoyl-sn-glycero-3-phosphoethanolamine, and N-{carbonyl-methoxy-polyethylene glycol-5000}-1,2-distearoyl-sn-glycero-3-phosphoethanolamine as components thereof, wherein the lipid membrane structure is a liposome, wherein the ratio by mole of adenosine to the total lipid content of the phospholipid and cholesterol contained in the lipid membrane structure is ranges from 0.01 to 2, wherein adenosine is administered in an amount effective to reduce the incidence of myocardial ischemia-reperfusion injury, said amount ranging from 2.25 mg/kg to 36 mg/kg, and wherein a therapeutic benefit is observed after a single dosage.